1. Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer. Issue 2 (6th January 2020) Authors: Takeuchi, Shinji; Hase, Tetsunari; Shimizu, Shinobu; Ando, Masahiko; Hata, Akito; Murakami, Haruyasu; Kawakami, Takahiro; Nagase, Katsuhiko; Yoshimura, Kenichi; Fujiwara, Tadami; Tanimoto, Azusa; Nishiyama, Akihiro; Arai, Sachiko; Fukuda, Koji; Katakami, Nobuyuki; Takahashi, Toshiaki; Hasegawa, Y... Journal: Cancer science Issue: Volume 111:Issue 2(2020) Page Start: 561 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗